GV1001 | Phase II (combined with cyclophosphamide) | Hepatocellular carcinoma (HCC) | No clear GV1001-specific immune responses 17/40 SD | Well-tolerated | 2010 | [52] |
| Phase I/II (combined with temozilomide) | Melanoma | Immune responses 5/25 PR, 6/25 SD | Well-tolerated | 2011 | [53] |
| Phase I/II | Lung and colon cancer and melanoma | Immune responses | Well-tolerated | 2012 | [54] |
| Phase I/II (combined with or without GM-CSF or gemcitabine) | Pancreatic cancer | Immune responses | Mild vaccination-related adverse events | 2014 | [55] |
| Phase III (GV1001 with or without gemcitabine and capecitabine) | Pancreatic cancer | Adding GV1001 to chemotherapy did not improve the overall survival of patients. | No additional adverse events | 2014 | [56] |
| Phase I/II (combined with hTERT540 peptides) | Non-small cell lung cancer (NSCLC) | Immune responses 7/26 SD (1/26CR after clinical trial) | Well-tolerated | 2006 | [57] |
| Phase I | Melanoma | Immune responses | Well-tolerated | 2011 | [58] |
UV1 | Phase I/IIa | Prostate cancer | Immune responses 17/22 SD | Injection site pruritus | 2017 | [59] |
Vx-001 | Phase I/II | NSCLC | Immune responses 8/22 SD | Well-tolerated; Local skin reactions | 2007 | [49] |
| Phase I/II (optimized Vx-001) | Breast cancer, colorectal cancer, head and neck cancer, HCC, melanoma, prostate cancer, kidney cancer, pancreatic cancer, cholangiocarcinoma, and others with advanced solid tumors, other than NSCLC | Immune responses 1/55 CR, 1/55 PR, 18/55 SD | Well-tolerated | 2012 | [50] |
| Phase I/II (optimized Vx-001-TERT(572Y)) | Chemo-resistant advanced solid tumors | Immune responses Better clinical outcome in responders than nonresponders | Well-tolerated | 2012 | [51] |
| Phase II | NSCLC | Immune responses 3/46 PR, 13/46 SD | Well-tolerated | 2014 | [60] |
Gx-301 | Phase I/II | Prostate and renal cancer | Immune responses | Well-tolerated | 2013 | [61] |
hTERT461 | Phase I | HCC | Immune responses | No significant adverse events | 2015 | [62] |
Dendritic cell vaccines | Phase I (Pulsed with hTERT540 peptide) | Breast and prostate cancer | Immune responses 4/7 SD | No significant adverse events | 2004 | [63] |
| Phase I/II (Transfected with hTERT mRNA) | Prostate cancer | Immune responses; a reduction of PSA and molecular clearance of circulating micrometastases | Well-tolerated | 2005 | [64] |
| Phase I/II (Pulsed with TERT540 peptide) | Prostate, breast, lung, colorectal, renal, head and neck cancer, and melanoma | Immune responses 4/16 PR | Well-tolerated; mild flu-like symptoms and fever | 2009 | [65] |
| Phase I/II (GRNVAC1) | Acute myeloid leukemia | Immune responses Favorable disease-free survival | Well-tolerated; local transient erythema | 2010 | [66] |
| Phase I/II (TAPCells vaccine) | Melanoma and prostate cancer | Immune responses | Well-tolerated | 2013 | [67] |
| Phase I (DC pulsed with hTERT572, CEA and survivin-derived peptides. | Pancreatic cancer | Immune responses 4/8 SD | Well-tolerated Fatigue and self-limiting flu-like symptoms | 2017 | [68] |